Crinetics Pharmaceuticals, Inc. Deferred Federal Income Tax Expense (Benefit)
Crinetics Pharmaceuticals, Inc. (CRNX) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-26
- Crinetics Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was $0.00.
- Crinetics Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $0.00.
- Crinetics Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |